Company: BLUWU
Filing Date: 2025-02-20
Form Type: S-1
Source: 0001493152-25-007630
Chunk: 199

Company: Blue Water Acquisition Corp. III
Filing Date: 2025-02-20
Form: S-1
Chunk 199
---
 journal (Ecology Letters) and has won numerous awards for his research and teaching. Mr. Coulson obtained his undergraduate degree in Biology from the University of York, and a PhD from Imperial College, London.We believe Mr. Coulson is qualified to serve on our Board of Directors due to his experience as an academic and research leader.

Dr. Trevor L. Hawkinswill serve as a member of our board of directors upon the effectiveness of the registration statement of which this prospectus forms a part. Dr. Hawkins has built a recognized career in the healthcare industry over the past 25 years spanning business, academic innovation and as an entrepreneur. Dr. Hawkins is a former director of the U.S. Department of Energy’s Human Genome Project and has diverse commercial and managerial experience at leading global companies. Dr. Hawkins currently serves on several boards in the life science industry. In April 2024, Dr. Hawkins was appointed to the Supervisory Board of Genomtec S.A., a public molecular diagnostics company based in Poland. He has been a member of the Board of Directors of Resistell AG, a medical technology company, since December 2023, and is also a member of the Science Advisory Boards of Noscendo GmbH and lifespin GmbH. Since January 2016, Dr. Hawkins has served as an Operating Advisor to GreyBird Ventures LLC, a venture capital firm focused on medical diagnostic solutions. Previously, Dr. Hawkins has held several senior executive roles at HP, GE, Siemens Healthcare and Philips. He was also a successful entrepreneur building and selling a diagnostic company based in Shanghai & San Francisco. Dr. Hawkins obtained a B.Sc. at the University of Sussex in the United Kingdom and completed a Ph.D. in Biochemistry from the Laboratory of Molecular Biology, Cambridge in 1993. We believe Dr. Hawkins’ experience as an entrepreneur, academic leader and business leader with diverse experience in global healthcare qualifies him to serve on our Board of Directors.

| 135 |

Prior Experience with Blank Check Companies

Our management team and board members possess experience in sponsoring and operating blank check companies, having served on the board or on the management team of various blank check companies as follows:

Blue Water Acquisition Corp. completed its initial public offering in December 2020 and consummated its business combination with Clarus Therapeutics Inc., a pharmaceutical company, in September 2021, in connection with which approximately 57% of the public shares were redeemed. Joseph Hernandez served as the chairman and chief executive officer of Blue Water I from May 2020 to September